China Journal of Leprosy and Skin Diseases ›› 2022, Vol. 38 ›› Issue (3): 185-188.doi: 10.12144/zgmfskin202203185

• Case Reports • Previous Articles     Next Articles

Rituximab combined with glucocorticoid in the treatment of refractory bullous pemphigoid: a case report

CHEN Xue1, TAN Cheng1, SHAN Minjie1, MIN Zhongsheng1, JI Jin1, CHEN Fang1, LIU Qing1, WU Hao2, PAN Yongzheng1   

  1. 1.Department of Dermatology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine,Nanjing 210029,China;
    2.Department of Oncology, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210000,China
  • Online:2022-03-15 Published:2022-01-05
  • Contact: PAN Yongzheng, E-mail: drpanyz@163.com

PDF (PC)

378

Like

Abstract: A 35-year-old male presented with erythema, papules and blisters on the lower extremitie for 1 month. The features of pathology, direct and indirect immunofluorescence and salt cracking test were in accordance with bullous pemphigoid. The efficacy of glucocorticoid, cyclophosphamide, combined with mycophenolate mofetil, thalidomide and intravenous injection of human immunoglobulin was poor. The lesions subsided after treated with rituximab injection combined glucocorticoid.

Key words: bullous pemphigoid, rituximab, refractory, ulcerative colitis